uracil has been researched along with Alloxan Diabetes in 19 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we explored whether alogliptin, a dipeptidyl peptidase-4 inhibitor, can prevent mitochondrial dysfunction and atrial remodeling in a diabetic rabbit model." | 7.85 | Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits. ( Jiang, N; Li, G; Li, J; Liang, X; Liu, T; Qiu, J; Tse, G; Wang, X; Yang, Y; Zhang, X; Zhang, Z; Zhao, Y, 2017) |
| " Alogliptin alleviated ventricular hypertrophy, interstitial fibrosis and diastolic dysfunction in diabetic rabbits." | 3.88 | Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits. ( Jiang, N; Li, G; Liu, C; Liu, R; Liu, T; Qiu, J; Suo, Y; Tse, G; Yang, Y; Zhang, X; Zhang, Z; Zhao, Y, 2018) |
| " In this study, we explored whether alogliptin, a dipeptidyl peptidase-4 inhibitor, can prevent mitochondrial dysfunction and atrial remodeling in a diabetic rabbit model." | 3.85 | Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits. ( Jiang, N; Li, G; Li, J; Liang, X; Liu, T; Qiu, J; Tse, G; Wang, X; Yang, Y; Zhang, X; Zhang, Z; Zhao, Y, 2017) |
| "Pioglitazone is a stimulator of nuclear receptor peroxisome proliferator-activated receptor gamma while alogliptin is a selective dipeptidyl peptidase IV inhibitor." | 1.39 | Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. ( Bell, GI; Chong, AS; Grossman, EJ; Misawa, R; Park, SY; Tao, J; Wang, XJ; Witkowski, P; Yin, H; Zhong, R, 2013) |
| "Alogliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor." | 1.37 | Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice. ( Huang, Y; Wang, J; Wang, Z; Zhang, X, 2011) |
| "Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4)." | 1.34 | Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. ( Asakawa, T; Feng, J; Gwaltney, SL; Kaldor, SW; Kassel, DB; Navre, M; Shi, L; Skene, RJ; Stafford, JA; Takeuchi, K; Wallace, MB; Webb, DR; Xu, R; Zhang, Z, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q | 2 |
| Deng, X | 2 |
| Jiang, N | 3 |
| Meng, L | 1 |
| Xing, J | 1 |
| Jiang, W | 1 |
| Xu, Y | 1 |
| Zhang, X | 3 |
| Zhang, Z | 3 |
| Zhao, Y | 2 |
| Qiu, J | 2 |
| Yang, Y | 2 |
| Li, J | 1 |
| Liang, X | 1 |
| Wang, X | 1 |
| Tse, G | 2 |
| Li, G | 2 |
| Liu, T | 2 |
| Han, L | 1 |
| Zhou, J | 1 |
| Zhang, H | 1 |
| Suo, Y | 1 |
| Liu, R | 1 |
| Liu, C | 1 |
| Wang, Y | 1 |
| Tang, X | 1 |
| Yi, L | 1 |
| Yin, H | 1 |
| Park, SY | 1 |
| Wang, XJ | 1 |
| Misawa, R | 1 |
| Grossman, EJ | 1 |
| Tao, J | 1 |
| Zhong, R | 1 |
| Witkowski, P | 1 |
| Bell, GI | 1 |
| Chong, AS | 1 |
| Pugazhenthi, S | 2 |
| Qin, L | 2 |
| Bouchard, R | 1 |
| Hirukawa, H | 1 |
| Kaneto, H | 1 |
| Shimoda, M | 1 |
| Kimura, T | 1 |
| Okauchi, S | 1 |
| Obata, A | 1 |
| Kohara, K | 1 |
| Hamamoto, S | 1 |
| Tawaramoto, K | 1 |
| Hashiramoto, M | 1 |
| Kaku, K | 1 |
| Chong, T | 1 |
| Rodriguez, R | 1 |
| Asakawa, T | 2 |
| Moritoh, Y | 2 |
| Kataoka, O | 1 |
| Suzuki, N | 1 |
| Takeuchi, K | 3 |
| Odaka, H | 1 |
| Hazama, M | 1 |
| Wang, Z | 1 |
| Huang, Y | 2 |
| Wang, J | 1 |
| Ta, NN | 1 |
| Schuyler, CA | 1 |
| Li, Y | 1 |
| Lopes-Virella, MF | 1 |
| Davidson, EP | 1 |
| Coppey, LJ | 1 |
| Dake, B | 1 |
| Yorek, MA | 1 |
| Feng, J | 1 |
| Wallace, MB | 1 |
| Stafford, JA | 1 |
| Kaldor, SW | 1 |
| Kassel, DB | 1 |
| Navre, M | 1 |
| Shi, L | 1 |
| Skene, RJ | 1 |
| Xu, R | 1 |
| Webb, DR | 1 |
| Gwaltney, SL | 1 |
| Viana, M | 1 |
| Aruoma, OI | 1 |
| Herrera, E | 1 |
| Bonet, B | 1 |
| Shevchuk, IA | 1 |
| Mel'nik, TF | 1 |
| Sanduliak, LI | 1 |
| Kashina, IM | 1 |
| Mardar', AM | 1 |
| Schmidt, R | 2 |
| Methfessel, J | 2 |
| Schultka, R | 1 |
| Apel, D | 1 |
| Keil, S | 1 |
19 other studies available for uracil and Alloxan Diabetes
| Article | Year |
|---|---|
Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Benzoic Acid; Cell Line; Cell Survival; Diabetes Mellitus, Experiment | 2021 |
Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits.
Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Experimental; Dipeptidyl-Peptida | 2017 |
Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Topics: Amides; Animals; Area Under Curve; Binding Sites; Catalytic Domain; Diabetes Mellitus, Experimental; | 2017 |
Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diastole; Dipeptidyl-Peptidase | 2018 |
Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhib | 2019 |
Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Synergism; Female; Gene Expressio | 2013 |
Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Blood Glucose; Cyclic AMP Response Element-Bin | 2015 |
Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Insulin Receptor Substrate Protein | 2015 |
Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Brain; Cytokines; Diabetes Mellitus, Experim | 2016 |
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Pepti | 2009 |
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Inositol; | 2010 |
Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Dose-Res | 2011 |
DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experime | 2011 |
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopa | 2011 |
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Topics: Animals; Binding Sites; Blood Glucose; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experi | 2007 |
Oxidative damage in pregnant diabetic rats and their embryos.
Topics: Adenine; Animals; Congenital Abnormalities; Cytosine; Diabetes Mellitus, Experimental; DNA Adducts; | 2000 |
[Experimental study of the content and histotopography of zinc in the pancreas].
Topics: Adrenal Glands; Adrenalectomy; Animals; Blood Glucose; Castration; Cobalt; Desoxycorticosterone; Dia | 1974 |
[Morphological and biochemical studies of the effect of barbituric acid, ureidosuccinic acid, orotic acid, uracil and thymine on the diabetogenic effect of alloxan].
Topics: Adrenal Glands; Alloxan; Amino Alcohols; Animals; Barbiturates; Blood Glucose; Diabetes Mellitus, Ex | 1968 |
[On the effect of pyrimidines and their precursors on the diabetogenic activity of alloxan].
Topics: Alloxan; Animals; Aspartic Acid; Barbiturates; Blood Glucose; Cytosine; Diabetes Mellitus, Experimen | 1966 |